In the bustling hub of South San Francisco, a groundbreaking collaboration has emerged between Circle Pharma, Inc., and Eli Lilly and Company. Circle Pharma, known for its trailblazing work in developing next-generation targeted macrocycle therapeutics for challenging cancers, has entered into an agreement with Eli Lilly to harness the power of Lilly TuneLab. This cutting-edge artificial intelligence and machine learning (AI/ML) platform by Lilly are designed to revolutionize the development of new medicines. By granting biotech companies access to potent drug discovery models trained on Lilly’s proprietary research data, this collaboration aims to drive innovation to new heights.
Circle Pharma is set to leverage Lilly TuneLab to amplify its AI/ML capabilities and enhance its proprietary MXMO platform. The MXMO platform stands as a beacon in overcoming critical hurdles in macrocycle drug development, paving the way for the creation of intrinsically cell-permeable and orally bioavailable macrocycle therapies. These advancements hold promise for targeting historically undruggable entities, presenting a new frontier in the battle against cancer. Notably, Circle Pharma’s lead program, CID-078, a groundbreaking orally bioavailable cyclin A/B RxL inhibitor, is currently under evaluation in a Phase 1 clinical trial for patients grappling with advanced solid tumors.
Constantine Kreatsoulas, Ph.D., the senior vice president and head of discovery technology sciences at Circle Pharma, expressed immense enthusiasm about the collaboration with Lilly. He emphasized the transformative potential of integrating TuneLab into their endeavors, particularly in fortifying the MXMO platform. This strategic partnership arrives at a pivotal juncture for Circle Pharma, with CID-078 making strides in clinical development and the preclinical pipeline rapidly advancing to tackle oncological challenges related to cyclins and other traditionally elusive targets.
The agreement between Circle Pharma and Eli Lilly stands as a testament to Lilly’s Catalyze360 model, a holistic initiative aimed at empowering early-stage biotechs. By providing access to capital, state-of-the-art lab facilities, cutting-edge technology, and a pool of drug development talent and resources, Lilly catalyzes breakthrough scientific endeavors. This collaborative spirit underscores the industry’s collective commitment to fostering innovation and driving therapeutic advancements.
Circle Pharma’s proprietary MXMO platform embodies a fusion of computationally driven drug design and sophisticated, fully synthetic macrocycle chemistry. The platform’s core essence lies in the meticulous screening of expansive permeability-biased physical and virtual macrocycle libraries to pinpoint early hit compounds. Leveraging Artificial Intelligence (AI), Machine Learning (ML), and rigorous physics-based simulations, Circle Pharma’s scientists navigate through a myriad of designs simultaneously, swiftly unraveling structure-activity relationships for hit-to-lead progression. The synthesis of diverse compounds in the lab, utilizing both natural and synthetic chemical building blocks, underscores Circle Pharma’s dedication to pushing the boundaries of innovation in macrocycle therapeutics.
In the realm of pharmaceutical journalism, Ruchika Sharma has carved a niche for herself as a Correspondent for the Business Section at Medical Dialogue. Her keen insights into the ever-evolving landscape of the pharmaceutical domain, coupled with her in-depth coverage of policy, insurance, healthcare business, and medical news, have positioned her as a trusted voice in the industry. With a strong academic foundation in Commerce and a postgraduate degree in Commerce, Sharma brings a unique perspective to her reporting, enriching the discourse on healthcare and pharmaceuticals.
Amidst the scientific discourse surrounding macrocycle therapeutics and AI/ML integration, it is crucial to highlight the transformative potential of this collaboration between Circle Pharma and Eli Lilly. By synergizing advanced technologies with innovative drug design strategies, these industry leaders are paving the way for novel therapeutic interventions in oncology and beyond. The convergence of computational prowess, synthetic chemistry, and artificial intelligence heralds a new era of precision medicine, where tailored treatments hold the promise of addressing unmet medical needs and propelling healthcare into a realm of unprecedented possibilities.
Takeaways:
– The collaboration between Circle Pharma and Eli Lilly signifies a paradigm shift in AI/ML integration for advancing macrocycle therapeutics.
– The MXMO platform’s fusion of computational drug design and synthetic chemistry holds immense potential for unlocking new avenues in drug discovery.
– Lilly’s Catalyze360 model exemplifies a holistic approach to empowering early-stage biotechs and fostering groundbreaking scientific endeavors.
– The integration of AI/ML technologies with drug development heralds a new era of precision medicine, offering tailored treatments for challenging medical conditions.
– Circle Pharma’s lead program, CID-078, exemplifies the innovative strides being made in developing orally bioavailable macrocycle therapies for solid tumors.
– Ruchika Sharma’s insightful reporting in the pharmaceutical domain sheds light on key industry trends and advancements, enriching the discourse on healthcare and medical innovations.
Tags: biotech
Read more on medicaldialogues.in